Literature DB >> 29632186

Programmed self-assembly of peptide-major histocompatibility complex for antigen-specific immune modulation.

Chih-Ping Mao1, Shiwen Peng1, Andrew Yang1, Liangmei He1, Ya-Chea Tsai1, Chien-Fu Hung1,2, T-C Wu3,2,4,5.   

Abstract

A technology to prime desired populations of T cells in the body-particularly those that possess low avidity against target antigen-would pave the way for the design of new types of vaccination for intractable infectious diseases or cancer. Here, we report such a technology based on positive feedback-driven, programmed self-assembly of peptide-major histocompatibility complex (pMHC) directly on the membrane of cognate T cells. Our design capitalizes on the unique features of the protein annexin V (ANXA5), which-in a concerted and synergistic manner-couples the early onset of TCR signaling by cognate pMHC with a surge in pMHC-TCR affinity, with repeated pMHC encounters, and with widespread TCR cross-linking. In our system, ANXA5 is linked to pMHC and firmly engages the plasma membrane of cognate T cells upon (and only upon) the early onset of TCR signaling. ANXA5, in turn, exerts a mechanical force that stabilizes interactions at the TCR-pMHC interface and facilitates repeated, serial pMHC encounters. Furthermore, ANXA5 quickly arranges into uniform 2D matrices, thereby prompting TCR cross-linking. Fusion of ANXA5 to pMHC augments lymphocyte activation by several orders of magnitude (>1,000-fold), bypasses the need for costimulation, and breaks tolerance against a model self-antigen in vivo. Our study opens the door to the application of synthetic, feedback-driven self-assembly platforms in immune modulation.

Entities:  

Keywords:  T cell signaling; annexin V; antigen-specific lymphocyte; immune modulation; protein self-assembly

Mesh:

Substances:

Year:  2018        PMID: 29632186      PMCID: PMC5924900          DOI: 10.1073/pnas.1718434115

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Annexin V binds to viable B cells and colocalizes with a marker of lipid rafts upon B cell receptor activation.

Authors:  S R Dillon; M Mancini; A Rosen; M S Schlissel
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

2.  Naive CD8+ T cells do not require costimulation for proliferation and differentiation into cytotoxic effector cells.

Authors:  B Wang; R Maile; R Greenwood; E J Collins; J A Frelinger
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

3.  High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.

Authors:  Sytse J Piersma; Ekaterina S Jordanova; Mariëtte I E van Poelgeest; Kitty M C Kwappenberg; Jeanette M van der Hulst; Jan W Drijfhout; Cornelis J M Melief; Gemma G Kenter; Gert Jan Fleuren; Rienk Offringa; Sjoerd H van der Burg
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

Review 4.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

5.  T cell receptor binding kinetics required for T cell activation depend on the density of cognate ligand on the antigen-presenting cell.

Authors:  Pablo A González; Leandro J Carreño; Daniel Coombs; Jorge E Mora; Edith Palmieri; Byron Goldstein; Stanley G Nathenson; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-16       Impact factor: 11.205

Review 6.  Annexins: linking Ca2+ signalling to membrane dynamics.

Authors:  Volker Gerke; Carl E Creutz; Stephen E Moss
Journal:  Nat Rev Mol Cell Biol       Date:  2005-06       Impact factor: 94.444

Review 7.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

9.  Annexin-A5 assembled into two-dimensional arrays promotes cell membrane repair.

Authors:  Anthony Bouter; Céline Gounou; Rémi Bérat; Sisareuth Tan; Bernard Gallois; Thierry Granier; Béatrice Langlois d'Estaintot; Ernst Pöschl; Bent Brachvogel; Alain R Brisson
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

10.  In search of a novel target - phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy.

Authors:  Sabrina Riedl; Beate Rinner; Martin Asslaber; Helmut Schaider; Sonja Walzer; Alexandra Novak; Karl Lohner; Dagmar Zweytick
Journal:  Biochim Biophys Acta       Date:  2011-07-26
View more
  3 in total

Review 1.  Annexin Animal Models-From Fundamental Principles to Translational Research.

Authors:  Thomas Grewal; Carles Rentero; Carlos Enrich; Mohamed Wahba; Carsten A Raabe; Ursula Rescher
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

2.  Delivery of IL-2 to the T Cell Surface Through Phosphatidylserine Permits Robust Expansion of CD8 T Cells.

Authors:  Alana MacDonald; Brandon Lam; John Lin; Louise Ferrall; Yu Jui Kung; Ya Chea Tsai; T-C Wu; Chien-Fu Hung
Journal:  Front Immunol       Date:  2021-11-04       Impact factor: 7.561

3.  Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.

Authors:  Malte Mohme; Cecile L Maire; Simon Schliffke; Simon A Joosse; Malik Alawi; Jakob Matschke; Ulrich Schüller; Judith Dierlamm; Tobias Martens; Klaus Pantel; Sabine Riethdorf; Katrin Lamszus; Manfred Westphal
Journal:  Acta Neuropathol Commun       Date:  2020-03-09       Impact factor: 7.801

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.